Ocular Therapeutix, Inc. (OCUL)
6.87
-0.51
(-6.91%)
USD |
NASDAQ |
Oct 16, 16:00
6.91
+0.04
(+0.58%)
After-Hours: 20:00
Ocular Therapeutix Free Cash Flow : -255.10M for June 30, 2026
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| June 30, 2026 | -255.10M |
| March 31, 2026 | -240.94M |
| December 31, 2025 | -216.89M |
| September 30, 2025 | -199.44M |
| June 30, 2025 | -179.37M |
| March 31, 2025 | -148.43M |
| December 31, 2024 | -135.96M |
| September 30, 2024 | -114.06M |
| June 30, 2024 | -90.59M |
| March 31, 2024 | -87.11M |
| December 31, 2023 | -76.32M |
| September 30, 2023 | -77.70M |
| June 30, 2023 | -78.49M |
| March 31, 2023 | -67.79M |
| December 31, 2022 | -63.32M |
| September 30, 2022 | -59.99M |
| June 30, 2022 | -59.29M |
| March 31, 2022 | -68.10M |
| December 31, 2021 | -66.74M |
| September 30, 2021 | -57.46M |
| June 30, 2021 | -58.07M |
| March 31, 2021 | -52.81M |
| December 31, 2020 | -54.40M |
| September 30, 2020 | -68.56M |
| Date | Value |
|---|---|
| June 30, 2020 | -74.06M |
| March 31, 2020 | -78.81M |
| December 31, 2019 | -79.82M |
| September 30, 2019 | -73.28M |
| June 30, 2019 | -65.26M |
| March 31, 2019 | -58.37M |
| December 31, 2018 | -51.12M |
| September 30, 2018 | -47.94M |
| June 30, 2018 | -53.01M |
| March 31, 2018 | -55.35M |
| December 31, 2017 | -58.72M |
| September 30, 2017 | -56.07M |
| June 30, 2017 | -47.85M |
| March 31, 2017 | -42.77M |
| December 31, 2016 | -35.92M |
| September 30, 2016 | -36.74M |
| June 30, 2016 | -38.31M |
| March 31, 2016 | -37.67M |
| December 31, 2015 | -35.52M |
| September 30, 2015 | -32.48M |
| June 30, 2015 | -29.31M |
| March 31, 2015 | -24.67M |
| December 31, 2014 | -21.76M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| EyePoint, Inc. | -271.28M |
| ANI Pharmaceuticals, Inc. | 167.52M |
| Eli Lilly & Co. | 13.56B |
| Corcept Therapeutics, Inc. | 106.92M |
| Veru, Inc. | -26.04M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -67.27M |
| Cash from Investing (Quarterly) | -3.367M |
| Cash from Financing (Quarterly) | 2.581M |
| Free Cash Flow Per Share (Quarterly) | -0.314 |
| Free Cash Flow to Equity (Quarterly) | -70.56M |
| Free Cash Flow to Firm (Quarterly) | -67.85M |
| Free Cash Flow Yield | -17.35% |